Taysha Gene Therapies - 6 Year Stock Price History | TSHA
Historical daily share price chart and data for Taysha Gene Therapies since 2020 adjusted for splits and dividends. The latest closing stock price for Taysha Gene Therapies as of May 20, 2026 is 5.49.
- The all-time high Taysha Gene Therapies stock closing price was 31.75 on January 20, 2021.
- The Taysha Gene Therapies 52-week high stock price is 7.30, which is 33% above the current share price.
- The Taysha Gene Therapies 52-week low stock price is 2.25, which is 59% below the current share price.
- The average Taysha Gene Therapies stock price for the last 52 weeks is 4.20.
| Taysha Gene Therapies Historical Annual Stock Price Data | ||||||
|---|---|---|---|---|---|---|
| Year | Average Stock Price | Year Open | Year High | Year Low | Year Close | Annual % Change |
| 2026 | 5.0982 | 5.2500 | 6.9800 | 4.0700 | 5.4900 | -0.18% |
| 2025 | 2.9081 | 1.8500 | 5.9100 | 1.1300 | 5.5000 | 217.92% |
| 2024 | 2.3159 | 1.7100 | 4.1700 | 1.2700 | 1.7300 | -2.26% |
| 2023 | 1.4729 | 2.2000 | 3.6600 | 0.5900 | 1.7700 | -21.68% |
| 2022 | 4.2602 | 11.8600 | 11.8600 | 1.3900 | 2.2600 | -80.60% |
| 2021 | 20.9748 | 26.1700 | 31.7500 | 11.4300 | 11.6500 | -56.10% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $1.290B | $0.010B |
| Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |